Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. A novel biomarker of endothelial function?

Atherosclerosis

Volumn 201, Issue 2, 2008, Pages 407-412

  Blanco Colio, Luis M ^a   Martín Ventura, José L ^a   Tuñón, José ^a   García Camarero, Tamara ^b   Berrazueta, José R ^b   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Coronary artery disease; Endothelium; Fas ligand; Plasma

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FAS LIGAND; GLYCERYL TRINITRATE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; FEMALE; FOREARM; HUMANS; HYPEREMIA; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASODILATION;

EID: 56649114587     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.02.005     Document Type: Article

References (24)

1. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
2. Widlansky M.E., Gokce N., Keaney Jr. J.F., et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42 (2003) 1149-1160
3. Vita J.A., and Keaney Jr. J.F. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
4. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
5. French L.E., Hahne M., Viard I., et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133 (1996) 335-343
6. Okumara K., and Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182 (1995) 1777-1783
7. Schneider P., Holler N., Bodmer J.C., et al. Conversion of membrane bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187 (1998) 1205-1213
8. Sata M., and Walsh K. TNF-alpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 4 (1998) 415-420
9. Blanco-Colio L.M., Martin-Ventura J.L., Sol J.M., et al. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 43 (2004) 1188-1194
10. Engelke K.A., Halliwill J.R., Proctor D.N., et al. Contribution of nitric oxide and prostaglandins to reactive hyperemia in human forearm. J Appl Physiol 81 (1996) 1807-1814
11. Cohen R.A., and Vanhoutte P.M. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92 (1995) 3337-3349
12. Sax F.L., Cannon III R.O., Hanson C., et al. Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function?. N Engl J Med 317 (1987) 1366-1370
13. Blanco-Colio L.M., Martin-Ventura J.L., de Teresa E., et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27 (2007) 168-174
14. Berrazueta J.R., Baghat K., Vallance P., et al. Dose and time-dependency of the dilator effects of the endothelin antagonist BQ123, in the human forearm. Br J Clin Pharmacol 44 (1997) 569-571
15. Benjamin N., Calver A., Collier J., et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25 (1995) 918-923
16. Patterson G.C., and Whelan R.F. Reactive hyperemia in the human forearm. Clin Sci 14 (1955) 197-201
17. Meredith I.T., Currie K.E., Anderson T.J., et al. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 270 (1996) H1435-H1440
18. Higashi Y., Sasaki S., Nakagawa K., et al. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol 87 (2001) 121-125
19. Mitchell G.F., Parise H., Vita J.A., et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham heart study. Hypertension 44 (2004) 134-139
20. Vita J.A., Keany J.F., Larson M.G., et al. Brachial artery vasodilator function and systemic inflammation in the Framingham offspring study. Circulation 110 (2004) 3604-3609
21. Griffith T.S., Brunner T., Fletcher S.M., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
22. Matter C.M., Chadjichristos C.E., Meier P., et al. Role of endogenous Fas (CD95/Apo-1) ligand in ballon-induced apoptosis, inflammation, and neointima formation. Circulation 113 (2006) 1879-1887
23. Kang S.M., Chung N., Kim J.Y., et al. Relation of vasodilator response of the brachial artery to inflammation markers in patients with coronary artery disease. Echocardiography 19 (2002) 661-667
24. Bernhard D., Csordas A., Henderson B., et al. Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J 19 (2005) 1096-1107